Top

Published in:

Open Access 01-12-2020 | Edema | Research article

Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients’ persistence

Published in: BMC Ophthalmology | Issue 1/2020

Abstract

Background

Intravitreal injections are a mandatory treatment for macular edema due to nAMD, DME and RVO. These chronic diseases usually need chronic treatment using intravitreal injections with anti-VEGF agents. Thus, many trials were performed to define the best treatment interval using pro re nata regimes (PRN), fixed regimes or treat-and-extend regimes (TE). However, real-world studies reveal a high rate of losing patients within a 2-year interval of treatment observation causing worse results. In this study we analyzed retrospectively 2 years of real-world experience with an individualized treat-and-extend injection scheme.

Methods

Since 2015 our treatment scheme for intravitreal injections has been switched from PRN to TE. Out of 102 patients 59 completed a follow up time of 2 years. Every patient received visual acuity testing, SD-OCT and slit lamp examination prior to every injection. At each visit an injection was performed and the treatment interval was adjusted mainly on SD-OCT based morphologic changes by increasing or reducing in 2-week steps. Individual changes of the treatment protocol by face-to-face communication between physician and patient were possible.

Results

After 1 year of treatment visual acuity gain in nAMD was 7.4 ± 2.2 ETDRS letters (n = 34; injection frequency: 7.4 ± 0.4) respectively 6.1 ± 4.7 in DME (n = 9; injection frequency: 8.4 ± 1.1) and 9.7 ± 4.5 in RVO (n = 16; injection frequency: 7.6 ± 0.5). After 2 years of treatment results were as following: nAMD: visual acuity gain 6.9 ± 2.1 (injection frequency: 12.6 ± 0.7); DME: 11.1 ± 5.1 (injection frequency: 14.0 ± 1.0); RVO: 7.5 ± 5.0 (injection frequency: 11.2 ± 0.9). Planned treatment exit after 2 year was achieved in 29.4% of patients in nAMD (0% after 1 year); 0% in DME (0% after 1 year); and 31.3% in RVO (0% after 1 year). Patients’ persistence was 94.1% during the follow-up.

Conclusion

Using a consequent and individualized TE regime in daily practice may lead to a high patients’ persistence and visual acuity gains nearly comparable to those of large prospective clinical trials. Crucial factors are face-to-face communication with the patient as well as a stringent management regime. At this time TE may be the only instrument for proactive therapy which should therefore be regarded as a first-line tool in daily practice.

Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol (Chicago, Ill 1960). 1998;116:653–8 http://www.ncbi.nlm.nih.gov/pubmed/9596502.CrossRef

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44. https://doi.org/10.1056/NEJMoa062655.CrossRefPubMed

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31. https://doi.org/10.1056/NEJMoa054481.CrossRefPubMed

Pielen A, Feltgen N, Isserstedt C, Callizo J, Junker B, Schmucker C. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One. 2013;8:e78538. https://doi.org/10.1371/journal.pone.0078538.CrossRefPubMedPubMedCentral

Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48. https://doi.org/10.1016/j.ophtha.2012.09.006.CrossRefPubMed

Ziemssen F, Wachtlin J, Kuehlewein L, Gamulescu M-A, Bertelmann T, Feucht N, et al. Intravitreal Ranibizumab therapy for diabetic macular edema in routine practice: two-year real-life data from a non-interventional, Multicenter Study in Germany. Diabetes Ther. 2018;9:2271–89. https://doi.org/10.1007/s13300-018-0513-2.CrossRefPubMedPubMedCentral

Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220–6. https://doi.org/10.1136/bjophthalmol-2014-305327.CrossRefPubMed

Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, et al. Aflibercept for patients with Neovascular age-related macular degeneration in routine clinical practice in Germany. Ophthalmol Retin. 2018;2:539–49. https://doi.org/10.1016/j.oret.2017.09.017.CrossRef

Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol. 2013;91:540–6. https://doi.org/10.1111/j.1755-3768.2012.02493.x.CrossRefPubMed

10.

Lala C, Framme C, Wolf-Schnurrbusch UEK, Wolf S. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration. Acta Ophthalmol. 2013;91:526–30. https://doi.org/10.1111/j.1755-3768.2012.02457.x.CrossRefPubMed

11.

Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251:697–704. https://doi.org/10.1007/s00417-012-2090-9.CrossRefPubMed

12.

Giannakaki-Zimmermann H, Ebneter A, Munk MR, Wolf S, Zinkernagel MS. Outcomes when switching from a pro re nata regimen to a treat and extend regimen using Aflibercept in Neovascular age-related macular degeneration. Ophthalmologica. 2016;236:201–6. https://doi.org/10.1159/000452929.CrossRefPubMed

13.

Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351–9. https://doi.org/10.1016/j.ophtha.2016.02.022.CrossRefPubMedPubMedCentral

14.

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. https://doi.org/10.1016/j.ophtha.2011.12.039.CrossRefPubMed

15.

Korobelnik J-F, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247–54. https://doi.org/10.1016/j.ophtha.2014.05.006.CrossRefPubMed

16.

Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155:429–437.e7. https://doi.org/10.1016/j.ajo.2012.09.026.CrossRefPubMed

17.

Pielen A, Clark WL, Boyer DS, Ogura Y, Holz FG, Korobelnik J-F, et al. Integrated results from the COPERNICUS and GALILEO studies. Clin Ophthalmol. 2017;11:1533–40. https://doi.org/10.2147/OPTH.S140665.CrossRefPubMedPubMedCentral

18.

Korobelnik J-F, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, et al. Intravitreal Aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology. 2014;121:202–8. https://doi.org/10.1016/j.ophtha.2013.08.012.CrossRefPubMed

19.

Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246–52. https://doi.org/10.1016/j.ophtha.2006.10.045.CrossRefPubMed

20.

Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201. https://doi.org/10.1016/j.ophtha.2013.08.011.CrossRefPubMed

21.

Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and visual acuity in Aflibercept and Ranibizumab therapy for Neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 2016;123:1521–9. https://doi.org/10.1016/j.ophtha.2016.03.037.CrossRefPubMed

22.

Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik J-F, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118:831–9. https://doi.org/10.1016/j.ophtha.2010.09.004.CrossRefPubMed

23.

Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663–71. https://doi.org/10.1016/j.ophtha.2010.12.019.CrossRefPubMed

24.

Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731–9. https://doi.org/10.1016/j.ophtha.2009.05.024.CrossRefPubMed

25.

Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405. https://doi.org/10.2337/dc10-0493.CrossRefPubMedPubMedCentral

26.

Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25. https://doi.org/10.1016/j.ophtha.2011.01.031.CrossRefPubMed

27.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124–1133.e1. https://doi.org/10.1016/j.ophtha.2010.02.022.CrossRefPubMed

28.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102–1112.e1. https://doi.org/10.1016/j.ophtha.2010.02.021.CrossRefPubMed

29.

Campochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L, et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology. 2014;121:2432–42. https://doi.org/10.1016/j.ophtha.2014.06.011.CrossRefPubMed

30.

Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14. https://doi.org/10.1016/j.ophtha.2014.04.024.CrossRefPubMed

31.

Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209–19. https://doi.org/10.1016/j.ophtha.2013.08.038.CrossRefPubMed

32.

Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–83. https://doi.org/10.1016/j.ophtha.2011.12.016.CrossRefPubMed

33.

Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802–9. https://doi.org/10.1016/j.ophtha.2011.12.005.CrossRefPubMed

34.

Januschowski K, Dimopoulos S, Szurman P, Feltgen N, Spitzer B, Pielen A, et al. Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study. Acta Ophthalmol. 2015;93:e400–2. https://doi.org/10.1111/aos.12600.CrossRefPubMed

35.

Prünte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnička J, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100:787–95. https://doi.org/10.1136/bjophthalmol-2015-307249.CrossRefPubMed

36.

Silva R, Berta A, Larsen M, Macfadden W, Feller C, Monés J, et al. Treat-and-extend versus monthly regimen in Neovascular age-related macular degeneration: results with Ranibizumab from the TREND study. Ophthalmology. 2018;125:57–65. https://doi.org/10.1016/j.ophtha.2017.07.014.CrossRefPubMed

Title: Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients’ persistence
Publication date: 01-12-2020
Keyword: Edema
Published in: BMC Ophthalmology / Issue 1/2020
Electronic ISSN: 1471-2415
DOI: https://doi.org/10.1186/s12886-020-01397-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients’ persistence

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Ultrasound findings in a case of Eales’ disease and ocular trauma with anterior chamber cholesterolosis

Lacrimal ductal cyst of the medial orbit: a case report

Preloaded vs manually loaded IOL delivery systems in cataract surgery in the largest ambulatory surgery center of northwestern China: an efficiency analysis

Bilateral multiple serous retinal detachments after treatment with nivolumab: a case report

Rectangular loop suture to correct iris capture of the posterior chamber intraocular lens

Reduction of corneal epithelial thickness during medical treatment for myopic regression following FS-LASIK